Spanish Court Ruling Clarifies Incompatibility Rules for Healthcare Professionals with Financial Interests in Pharmaceutical Companies

A recent ruling by the Superior Court of Justice of the Basque Country is clarifying the scope of incompatibility rules for healthcare professionals who may have financial interests in pharmaceutical companies. The case, Judgment No. 483/2025 (ECLI:ES:TSJPV:2025:3706), centers on the interpretation of Royal Legislative Decree 1/2015, of July 24, which consolidates the Law on guarantees and rational use of medicines and health products. The court’s decision balances the require to maintain independence in prescribing practices with the constitutional right to freedom of enterprise.

Legal Framework

Article 4.1 of Royal Legislative Decree 1/2015 establishes incompatibility between the practice of medicine (including prescribing) and “any kind of direct economic interests derived from the manufacturing, preparation, distribution, intermediation and marketing of medicines and health products.” This is set against the backdrop of Article 38 of the Spanish Constitution, which protects freedom of enterprise.

Background of the Case

The case involved two companies within the same business group seeking authorization to operate as retail commercial establishments for veterinary medicines. A third company within the same group was already engaged in veterinary clinical practice. All three companies shared the same ownership structure and operated independently with separate teams. The Pharmacy Directorate of the Basque Government initially denied the authorizations, citing concerns that allowing these companies to dispense veterinary medicines would violate Article 4.1 of Royal Legislative Decree 1/2015 due to the shared business group structure. This denial was upheld by the Deputy Minister of Health Administration and Financing, leading to a challenge in the contentious-administrative jurisdiction.

The Court’s Decision

The Court overturned the Administration’s decision, arguing that the incompatibility rule applies to the healthcare professional (as an individual), not to the legal entity itself. The court found that the Administration had not demonstrated that any individual healthcare professional had a direct economic interest in the marketing of medicines. The denial was based solely on the group’s structure, without the individualized analysis required by the law.

The Court further clarified that membership in a business group creates, at most, an indirect interest. Even if the rule could apply to legal entities, the economic benefit derived from belonging to a holding company is not considered a “direct” interest. The court reasoned that any benefits accrue to the parent company, not directly to the company or professional in question, as the entities have distinct legal personalities.

Key Takeaways

• The ruling emphasizes a restrictive interpretation of the incompatibility rules outlined in Royal Legislative Decree 1/2015.
• The mere existence of a corporate holding structure is insufficient to presume a “direct economic interest.”
• The Administration must demonstrate that a prescribing professional has a personal and direct economic interest in the marketing of medicines, or that the corporate structure operates as a single, unified entity.

The Court’s Ruling delimits the scope of the incompatibility of article 4.1 of Royal Legislative Decree 1/2015 in the context of business groups. This decision protects freedom of enterprise while reinforcing the importance of independent medical judgment.